aid: arthrosi-therapeutics
name: Arthrosi Therapeutics
description: 'Arthrosi Therapeutics, Inc. is a late-stage clinical biotechnology company
  founded in 2018 and headquartered in San Diego, California, by a team of gout specialists
  who previously led first-generation urate-transporter development at Ardea Biosciences.
  Its lead candidate, pozdeutinurad (AR882), is a once-daily oral next-generation URAT1
  inhibitor in two fully enrolled replicate global Phase 3 trials (REDUCE 1 and REDUCE
  2) for progressive and tophaceous gout, backed by roughly $299M in venture financing
  including a $153M Series E led by Prime Eight Capital. Sobi (Swedish Orphan Biovitrum)
  completed its acquisition of Arthrosi on 9 February 2026. Arthrosi is a drug developer,
  not a software company: it operates a WordPress corporate site with company, leadership
  and news pages, and publishes no developer portal, public API, SDK, package or machine-readable
  specification of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/arthrosi-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Clinical Trials
- Drug Development
- Gout
- Rheumatology
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/arthrosi-therapeutics-domain-security.yml
- type: Website
  url: https://arthrosi.com/
- type: About
  url: https://arthrosi.com/company/
- type: Team
  url: https://arthrosi.com/team/
- type: Blog
  url: https://arthrosi.com/news-media/
- type: LinkedIn
  url: https://www.linkedin.com/company/arthrosi-therapeutics-inc
- type: SecondaryMarket
  url: https://forgeglobal.com/arthrosi-therapeutics_stock/
- type: LLMsTxt
  url: llms/arthrosi-therapeutics-llms.txt
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Arthrosi is a San Diego drug developer whose product is a Phase 3 oral gout molecule
    (pozdeutinurad/AR882, acquired by Sobi in February 2026), not software — there is no
    GitHub org, no package on any registry and no api/docs/developer subdomain in DNS, and
    its single web property is a WordPress marketing site that answers HTTP 202 with a
    SiteGround sgcaptcha interstitial to every path including /robots.txt and a bogus
    control path, so even the marketing copy is machine-unreadable.
  evidence:
  - url: https://arthrosi.com/robots.txt
    status: 202
  - url: https://arthrosi.com/.well-known/agent-card.json
    status: 202
  - url: https://api.github.com/orgs/arthrosi
    status: 404
  - url: https://pypi.org/pypi/arthrosi/json
    status: 404
  checked: '2026-08-06'